ABC Arbitrage SA Has $24.80 Million Holdings in Smith & Nephew SNATS, Inc. $SNN

ABC Arbitrage SA lowered its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 23.9% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 683,452 shares of the medical equipment provider’s stock after selling 215,183 shares during the quarter. Smith & Nephew SNATS accounts for approximately 2.4% of ABC Arbitrage SA’s investment portfolio, making the stock its 11th biggest holding. ABC Arbitrage SA owned 0.16% of Smith & Nephew SNATS worth $24,802,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of SNN. AlphaCore Capital LLC bought a new position in shares of Smith & Nephew SNATS in the second quarter worth $44,000. Smartleaf Asset Management LLC increased its position in shares of Smith & Nephew SNATS by 1,222.3% in the third quarter. Smartleaf Asset Management LLC now owns 2,486 shares of the medical equipment provider’s stock valued at $88,000 after acquiring an additional 2,298 shares during the period. Root Financial Partners LLC purchased a new position in shares of Smith & Nephew SNATS during the third quarter valued at approximately $102,000. Bessemer Group Inc. increased its position in shares of Smith & Nephew SNATS by 111.9% during the second quarter. Bessemer Group Inc. now owns 3,709 shares of the medical equipment provider’s stock valued at $114,000 after buying an additional 1,959 shares during the period. Finally, MAI Capital Management grew its stake in Smith & Nephew SNATS by 24.0% in the second quarter. MAI Capital Management now owns 4,371 shares of the medical equipment provider’s stock worth $134,000 after purchasing an additional 846 shares during the period. 25.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SNN has been the subject of several recent analyst reports. Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a research note on Monday, November 17th. Royal Bank Of Canada lowered shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Sanford C. Bernstein set a $37.50 target price on Smith & Nephew SNATS and gave the stock a “market perform” rating in a report on Tuesday, October 14th. Finally, Wall Street Zen raised shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 10th. One research analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $35.75.

Smith & Nephew SNATS Price Performance

Shares of SNN opened at $35.38 on Wednesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. The stock’s 50 day moving average is $33.32 and its two-hundred day moving average is $34.73. Smith & Nephew SNATS, Inc. has a 12 month low of $23.91 and a 12 month high of $38.79.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.